[A17-42] Brodalumab (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V
Last updated 01.12.2017
Project no.:
A17-42
Commission:
Commission awarded on 01.09.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Skin and hair
Adult patients with moderate to severe plaque psoriasis for whom systemic treatment is an option
In case of contraindication, intolerance or inadequate response to other systemic treatments including ciclosporin, methotrexate or PUVA: hint of non-quantifiable added benefit. Other patients: lesser benefit or added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-02 | Brodalumab (plaque psoriasis) - Addendum to Commission A17-42 | Commission completed |
Federal Joint Committee (G-BA)
2018-03-01 A G-BA decision was published.